Antheia Announces New Financing and Plans to Construct Pilot Plant Facility for Biomanufacturing
Summary
"As we advance our entire pipeline of pharmaceutical candidates, investing in our own on-site facility will be critical for optimizing strain performance and improving efficiency as we move to industrial scale production. "Antheia is utilizing synthetic biology to create both existing and new medicines in more controlled and economical ways," said Christopher A. Herr, Senior Managing Director at Oxford Finance. ""Were thrilled to support Antheia and their mission to disrupt the traditional agricultural-based supply chain and accelerate the discovery of new medicines," said Peter Sletteland, Director of Life Science and Healthcare at Silicon Valley Bank. "Antheia aims to transform the supply chain for plant-based APIs that are critical to the development of many essential medicines, yet reliant on fragile, unpredictable, inefficient, and costly agriculture-based sources. Oxford is headquartered in Alexandria, Virginia, with additional offices in California (San Diego, Palo Alto, and Los Angeles), and the greater Boston and New York City metropolitan areas.